| Product NDC: | 0173-0750 |
| Proprietary Name: | TREXIMET |
| Non Proprietary Name: | sumatriptan and naproxen sodium |
| Active Ingredient(s): | 500; 85 mg/1; mg/1 & nbsp; sumatriptan and naproxen sodium |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0173-0750 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021926 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20080425 |
| Package NDC: | 0173-0750-49 |
| Package Description: | 9 TABLET, FILM COATED in 1 BOTTLE (0173-0750-49) |
| NDC Code | 0173-0750-49 |
| Proprietary Name | TREXIMET |
| Package Description | 9 TABLET, FILM COATED in 1 BOTTLE (0173-0750-49) |
| Product NDC | 0173-0750 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | sumatriptan and naproxen sodium |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20080425 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE |
| Strength Number | 500; 85 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Serotonin 1b Receptor Agonists [MoA],Serotonin 1d Receptor Agonists [MoA],Serotonin-1b and Serotonin-1d Receptor Agonist [EPC],Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC] |